A phase I NANT study of lenalidomide with ch14.18 and isotretinoin (RA) in patients with refractory/recurrent neuroblastoma (RR-NB).
2018
10522Background: Ch14.18 (dinutuximab) increases event free and overall survival in patients with high-risk NB when given in a regimen with GM-CSF/IL-2. However, this therapy has significant toxici...
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI